Association of IL-4 and IL-10 maternal haplotypes with immune responses to P. falciparum in mothers and newborns

BMC Infectious Diseases

Florence Migot-Nabias²  André Garcia²  Achille Massougbodji¹  Benjamin Fayomi⁵  Audrey Sabbagh²  Claude Ahouangninou³  Désiré Bonou³  Julien Noukpo³  Rodolphe Ladékpo³  Agnès Le Port²  David Courtin³  Aziz Bouraïma³  Célia Dechavanne²  Adjimon Gatien Lokossou⁴ 

[1]Laboratoire de Parasitologie, Faculté des Sciences de la Santé, Cotonou, Bénin

[2]PRES Sorbonne Paris Cité, Université Paris Descartes, Faculté de Pharmacie, Paris, France

[3]Centre d’Étude et de Recherche sur le Paludisme Associé à la Grossesse et l’Enfance (CERPAGE), Cotonou, Bénin

[4]Present address: CRCHUM-Hôpital Saint-Luc, 264 boulevard René-Lévesque Est, Montreal (Quebec) H2X 1P1, Canada

[5]Institut des Sciences Biomédicales Appliquées, Cotonou, Bénin

关键词: Specific antibodies;    Recombinant proteins;    Cord blood;    Pregnancy;    IL-13;    IL-10;    IL-4;    Cytokine gene polymorphisms;    P. falciparum;    Malaria;   

Others  :  1148494
DOI  :  10.1186/1471-2334-13-215

 received in 2012-09-13, accepted in 2013-05-03,  发布年份 2013

【 摘 要 】

Background

Particular cytokine gene polymorphisms are involved in the regulation of the antibody production. The consequences of already described IL-4, IL-10 and IL-13 gene polymorphisms on biological parameters and antibody levels were investigated among 576 mothers at delivery and their newborns in the context of P. falciparum placental malaria infection.

Methods

The study took place in the semi-rural area of Tori-Bossito, in south-west Benin, where malaria is meso-endemic. Six biallelic polymorphisms were determined by quantitative PCR using TaqMan® Pre-Designed SNP Genotyping Assays, in IL-4 (rs2243250, rs2070874), IL-10 (rs1800896, rs1800871, rs1800872) and IL-13 (rs1800925) genes. Antibody responses directed to P. falciparum MSP-1, MSP-2, MSP-3, GLURP-R0, GLURP-R2 and AMA-1 recombinant proteins were determined by ELISA.

Results

The maternal IL-4₋₅₉₀*T/IL-4₊₃₃*T haplotype (one or two copies) was associated with favorable maternal condition at delivery (high haemoglobin levels, absence of placental parasites) and one of its component, the IL-4₋₅₉₀TT genotype, was related to low IgG levels to MSP-1, MSP-2/3D7 and MSP-2/FC27. Inversely, the maternal IL-10₋₁₀₈₂AA was positively associated with P. falciparum placenta infection at delivery. As a consequence, the IL-10₋₈₁₉*T allele (in CT and TT genotypes) as well as the IL-10₋₁₀₈₂*A/IL-10₋₈₁₉*T/IL-10₋₅₉₂*A haplotype (one or two copies) in which it is included, were related to an increased risk for anaemia in newborns. The maternal IL-10₋₁₀₈₂AA genotype was related to high IgG levels to MSP-2/3D7 and AMA-1 in mothers and newborns, respectively. The IL-13 gene polymorphism was only involved in the newborn’s antibody response to AMA-1.

Conclusion

These data revealed that IL-4 and IL-10 maternal gene polymorphisms are likely to play a role in the regulation of biological parameters in pregnant women at delivery (anaemia, P. falciparum placenta infection) and in newborns (anaemia). Moreover, IL-4, IL-10 and IL-13 maternal gene polymorphisms were related to IgG responses to MSP-1, MSP-2/3D7 and MSP-2/FC27 in mothers as well as to AMA-1 in newborns.

【 授权许可】

   
2013 Lokossou et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Dessein AJ, Chevillard C, Marquet S, Henri S, Hillaire D, Dessein H: Genetics of parasitic infections. Drug Metab Dispos 2001, 29(4 Pt 2):484-488.
• [2]Flori L, Kumulungui B, Aucan C, Esnault C, Traore AS, Fumoux F, Rihet P: Linkage and association between Plasmodium falciparum blood infection levels and chromosome 5q31-q33. Genes Immun 2003, 4(4):265-268.
• [3]Garcia A, Cot M, Chippaux J-P, Ranque S, Feingold J, Demenais F, Abel L: Genetic control of blood infection levels in human malaria: evidence for a complex genetic model. AmJTrop Med Hyg 1998, 58(4):480-488.
• [4]Marquet S, Abel L, Hillaire D, Dessein H, Kalil J, Feingold J, Weissenbach J, Dessein AJ: Genetic localization of a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. Nat Genet 1996, 14(2):181-184.
• [5]Rihet P, Abel L, Traoré Y, Traoré-Leroux T, Aucan C, Fumoux F: Human malaria: segregation analysis of blood infection levels in a suburban area and a rural area in Burkina Faso. Genet Epidemiol 1998, 15(5):435-450.
• [6]Garcia A, Marquet S, Bucheton B, Hillaire D, Cot M, Fievet N, Dessein AJ, Abel L: Linkage analysis of blood Plasmodium falciparum levels: interest of the 5q31-q33 chromosome region. AmJTrop Med Hyg 1998, 58(6):705-709.
• [7]Sakuntabhai A, Ndiaye R, Casadémont I, Peerapittayamongkol C, Rogier C, Tortevoye P, Tall A, Paul R, Turbpaiboon C, Phimpraphi W, Trape JF, Spiegel A, Heath S, Mercereau-Puijalon O, Dieye A, Julier C: Genetic determination and linkage mapping of Plasmodium falciparum malaria related traits in Senegal. PLoS One 2008, 3(4):e2000.
• [8]Malaguarnera L, Musumeci S: The immune response to Plasmodium falciparum malaria. Lancet Infect Dis 2002, 2(8):472-478.
• [9]Marsh DG, Neely JD, Breazeale DR, Ghosh B, Freidhoff LR, Ehrlich-Kautzky E, Schou C, Krishnaswamy G, Beaty TH: Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science 1994, 264(5162):1152-1156.
• [10]Vercelli D: Regulation of IgE synthesis. Allergy Proc 1993, 14(6):413-416.
• [11]Troye-Blomberg M, Riley EM, Kabilan L, Holmberg M, Perlmann H, Andersson U, Heusser CH, Perlmann P: Production by activated human T cells of interleukin 4 but not interferon-gamma is associated with elevated levels of serum antibodies to activating malaria antigens. Proc Natl Acad Sci USA 1990, 87(14):5484-5488.
• [12]Rousset F, Garcia E, Defrance T, Péronne C, Vezzio N, Hsu DH, Kastelein R, Moore KW, Banchereau J: Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992, 89(5):1890-1893.
• [13]Troye-Blomberg M, Berzins K, Perlmann P: T-cell control of immunity to the asexual blood stages of the malaria parasite. Crit Rev Immunol 1994, 14(2):131-155.
• [14]Wynn TA: IL-13 effector functions. Annu Rev Immunol 2003, 21:425-456.
• [15]de Mendonca VR, Goncalves MS, Barral-Netto M: The host genetic diversity in malaria infection. J Trop Med 2012, 2012:940616.
• [16]Ohashi J, Naka I, Patarapotikul J, Hananantachai H, Looareesuwan S, Tokunaga K: A single-nucleotide substitution from C to T at position −1055 in the IL-13 promoter is associated with protection from severe malaria in Thailand. Genes Immun 2003, 4(7):528-531.
• [17]Rosenwasser LJ, Klemm DJ, Dresback JK, Inamura H, Mascali JJ, Klinnert M, Borish L: Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy 1995, 25(Suppl 2):74-78. discussion 95–6
• [18]Luoni G, Verra F, Arcà B, Sirima BS, Troye-Blomberg M, Coluzzi M, Kwiatkowski D, Modiano D: Antimalarial antibody levels and IL4 polymorphism in the Fulani of West Africa. Genes Immun 2001, 2(7):411-414.
• [19]Vafa M, Maiga B, Berzins K, Hayano M, Bereczky S, Dolo A, Daou M, Arama C, Kouriba B, Färnert A, Doumbo OK, Troye-Blomberg M: Associations between the IL-4–590 T allele and Plasmodium falciparum infection prevalence in asymptomatic Fulani of Mali. Microbes Infect 2007, 9(9):1043-1048.
• [20]Vafa M, Maiga B, Israelsson E, Dolo A, Doumbo OK, Troye-Blomberg M: Impact of the IL-4–590 C/T transition on the levels of Plasmodium falciparum specific IgE, IgG, IgG subclasses and total IgE in two sympatric ethnic groups living in Mali. Microbes Infect 2009, 11(8–9):779-784.
• [21]Gyan BA, Goka B, Cvetkovic JT, Kurtzhals JL, Adabayeri V, Perlmann H, Lefvert AK, Akanmori BD, Troye-Blomberg M: Allelic polymorphisms in the repeat and promoter regions of the interleukin-4 gene and malaria severity in Ghanaian children. Clin Exp Immunol 2004, 138(1):145-150.
• [22]Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV: An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997, 24(1):1-8.
• [23]Carpenter D, Abushama H, Bereczky S, Färnert A, Rooth I, Troye-Blomberg M, Quinnell RJ, Shaw MA: Immunogenetic control of antibody responsiveness in a malaria endemic area. Hum Immunol 2007, 68(3):165-169.
• [24]Salhi A, Rodrigues V Jr, Santoro F, Dessein H, Romano A, Castellano LR, Sertorio M, Rafati S, Chevillard C, Prata A, Alcaïs A, Argiro L, Dessein A: Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J Immunol 2008, 180(9):6139-6148.
• [25]Ouma C, Davenport GC, Were T, Otieno MF, Hittner JB, Vulule JM, Martinson J, Ong’echa JM, Ferrell RE, Perkins DJ: Haplotypes of IL-10 promoter variants are associated with susceptibility to severe malarial anemia and functional changes in IL-10 production. Hum Genet 2008, 124(5):515-524.
• [26]Le Hesran JY, Cot M, Personne P, Fievet N, Dubois B, Beyemé M, Boudin C, Deloron P: Maternal placental infection with Plasmodium falciparum and malaria morbidity during the first 2 years of life. Am J Epidemiol 1997, 146(10):826-831.
• [27]Mutabingwa TK, Bolla MC, Li JL, Domingo GJ, Li X, Fried M, Duffy PE: Maternal malaria and gravidity interact to modify infant susceptibility to malaria. PLoS Med 2005, 2(12):e407.
• [28]Schwarz NG, Adegnika AA, Breitling LP, Gabor J, Agnandji ST, Newman RD, Lell B, Issifou S, Yazdanbakhsh M, Luty AJ, Kremsner PG, Grobusch MP: Placental malaria increases malaria risk in the first 30 months of life. Clin Infect Dis 2008, 47(8):1017-1025.
• [29]Courtin D, Oesterholt M, Huismans H, Kusi K, Milet J, Badaut C, Gaye O, Roeffen W, Remarque EJ, Sauerwein R, Garcia A, Luty AJ: The quantity and quality of African children’s IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria. PLoS One 2009, 4(10):e7590.
• [30]Dodoo D, Theisen M, Kurtzhals JA, Akanmori BD, Koram KA, Jepsen S, Nkrumah FK, Theander TG, Hviid L: Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis 2000, 181(3):1202-1205.
• [31]Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, Aikawa M, Filgueira MC, Tartar A, Druilhe P: Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 1994, 84(5):1594-1602.
• [32]McGregor IA, Wilson ME, Billewicz WZ: Malaria infection of the placenta in The Gambia, West Africa; its incidence and relationship to stillbirth, birthweight and placental weight. Trans R Soc Trop Med Hyg 1983, 77(2):232-244.
• [33]Theisen M, Soe S, Brunstedt K, Follmann F, Bredmose L, Israelsen H, Madsen SM, Druilhe P: A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. Vaccine 2004, 22(9–10):1188-1198.
• [34]Branch OH, Udhayakumar V, Hightower AW, Oloo AJ, Hawley WA, Nahlen BL, Bloland PB, Kaslow DC, Lal AA: A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. AmJTrop Med Hyg 1998, 58(2):211-219.
• [35]Pan W, Huang D, Zhang Q, Qu L, Zhang D, Zhang X, Xue X, Qian F: Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro. J Immunol 2004, 172(10):6167-6174.
• [36]Osier FH, Fegan G, Polley SD, Murungi L, Verra F, Tetteh KK, Lowe B, Mwangi T, Bull PC, Thomas AW, Cavanagh DR, McBride JS, Lanar DE, Mackinnon MJ, Conway DJ, Marsh K: Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 2008, 76(5):2240-2248.
• [37]Le Port A, Cottrell G, Martin-Prevel Y, Migot-Nabias F, Cot M, Garcia A: First malaria infections in a cohort of infants in Benin: biological, environmental and genetic determinants. Description of the study site, population methods and preliminary results. BMJ Open 2012, 2(2):e000342.
• [38]Cottrell G, Kouwaye B, Pierrat C, Le Port A, Bouraïma A, Fonton N, Hounkonnou MN, Massougbodji A, Corbel V, Garcia A: Modeling the influence of local environmental factors on malaria transmission in Benin and its implications for cohort study. PLoS One 2012, 7(1):e28812.
• [39]Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, Tiono AB, Konate AT, Chilengi R, Theisen M, Dodoo D, Remarque E, Bosomprah S, Milligan P, Sirima SB: Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso. West Africa. Infect Immun 2008, 76(2):759-766.
• [40]Bonnet S, Pêtres S, Holm I, Fontaine T, Rosario S, Roth C, Longacre S: Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate. Vaccine 2006, 24(33–34):5997-6008.
• [41]Kocken CH, Withers-Martinez C, Dubbeld MA, van der Wel A, Hackett F, Valderrama A, Blackman MJ, Thomas AW: High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect Immun 2002, 70(8):4471-4476.
• [42]McCarthy JS, Marjason J, Elliott S, Fahey P, Bang G, Malkin E, Tierney E, Aked-Hurditch H, Adda C, Cross N, Richards JS, Fowkes FJ, Boyle MJ, Long C, Druilhe P, Beeson JG, Anders RF: A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720. PLoS One 2011, 6(9):e24413.
• [43]Carvalho LJ, Oliveira SG, Theisen M, Alves FA, Andrade MC, Zanini GM, Brígido MC, Oeuvray C, Póvoa MM, Muniz JA, Druilhe P, Daniel-Ribeiro CT: Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels. Scand J Immunol 2004, 59(4):363-372.
• [44]Theisen M, Vuust J, Gottschau A, Jepsen S, Høgh B: Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli. Clin Diagn Lab Immunol 1995, 2(1):30-34.
• [45]Hill WG, Robertson A: Linkage disequilibrium in finite populations. Theor Appl Genet 1968, 38:226-231.
• [46]Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21(2):263-265.
• [47]Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D: The structure of haplotype blocks in the human genome. Science 2002, 296(5576):2225-2229.
• [48]Stephens M, Donnelly P: A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003, 73(5):1162-1169.
• [49]Excoffier L, Laval G, Schneider S: Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinform Online 2007, 1:47-50.
• [50]Koura GK, Ouedraogo S, Le Port A, Watier L, Cottrell G, Guerra J, Choudat I, Rachas A, Bouscaillou J, Massougbodji A, Garcia A: Anaemia during pregnancy: impact on birth outcome and infant haemoglobin level during the first 18 months of life. Trop Med Int Health 2012, 17(3):283-291.
• [51]Jha AN, Singh VK, Kumari N, Singh A, Antony J, van Tong H, Singh S, Pati SS, Patra PK, Singh R, Toan NL, le Song H, Assaf A, Messias-Reason IJ, Velavan TP, Singh L, Thangaraj K: IL-4 haplotype -590T, -34T and intron-3 VNTR R2 is associated with reduced malaria risk among ancestral indian tribal populations. PLoS One 2012, 7(10):e48136.
• [52]Dybedal I, Larsen S, Jacobsen SE: IL-12 directly enhances in vitro murine erythropoiesis in combination with IL-4 and stem cell factor. J Immunol 1995, 154(10):4950-4955.
• [53]Metzger WG, Okenu DM, Cavanagh DR, Robinson JV, Bojang KA, Weiss HA, McBride JS, Greenwood BM, Conway DJ: Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. Parasite Immunol 2003, 25(6):307-312.
• [54]Tangteerawatana P, Perlmann H, Hayano M, Kalambaheti T, Troye-Blomberg M, Khusmith S: IL4 gene polymorphism and previous malaria experiences manipulate anti-Plasmodium falciparum antibody isotype profiles in complicated and uncomplicated malaria. Malar J 2009, 8:286. BioMed Central Full Text
• [55]Vidyarani M, Selvaraj P, Prabhu Anand S, Jawahar MS, Adhilakshmi AR, Narayanan PR: Interferon gamma (IFNgamma) &interleukin-4 (IL-4) gene variants & cytokine levels in pulmonary tuberculosis. Indian J Med Res 2006, 124(4):403-410.
• [56]Kumaratilake LM, Ferrante A, Jaeger T, Rzepczyk C: GM-CSF-induced priming of human neutrophils for enhanced phagocytosis and killing of asexual blood stages of Plasmodium falciparum: synergistic effects of GM-CSF and TNF. Parasite Immunol 1996, 18(3):115-123.
• [57]Cabantous S, Poudiougou B, Oumar AA, Traore A, Barry A, Vitte J, Bongrand P, Marquet S, Doumbo O, Dessein AJ: Genetic evidence for the aggravation of Plasmodium falciparum malaria by interleukin 4. J Infect Dis 2009, 200(10):1530-1539.
• [58]King CL, Malhotra I, Wamachi A, Kioko J, Mungai P, Wahab SA, Koech D, Zimmerman P, Ouma J, Kazura JW: Acquired immune responses to Plasmodium falciparum merozoite surface protein-1 in the human fetus. J Immunol 2002, 168(1):356-364.
• [59]Xi G, Leke RG, Thuita LW, Zhou A, Leke RJ, Mbu R, Taylor DW: Congenital exposure to Plasmodium falciparum antigens: prevalence and antigenic specificity of in utero-produced antimalarial immunoglobulin M antibodies. Infect Immun 2003, 71(3):1242-1246.
• [60]Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP: Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun 2000, 1(3):185-190.
• [61]Mangia A, Santoro R, Piattelli M, Pazienza V, Grifa G, Iacobellis A, Andriulli A: IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. Cytokine 2004, 25(3):103-109.
• [62]Moore KW, de Waal MR, Coffman RL, O’Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
• [63]Kilpinen S, Huhtala H, Hurme M: The combination of the interleukin-1alpha (IL-1alpha-889) genotype and the interleukin-10 (IL-10 ATA) haplotype is associated with increased interleukin-10 (IL-10) plasma levels in healthy individuals. Eur Cytokine Netw 2002, 13(1):66-71.
• [64]Gatlin MR, Black CL, Mwinzi PN, Secor WE, Karanja DM, Colley DG: Association of the gene polymorphisms IFN-gamma +874, IL-13–1055 and IL-4–590 with patterns of reinfection with Schistosoma mansoni. PLoS Negl Trop Dis 2009, 3(2):e375.
• [65]Kouriba B, Traore HA, Dabo A, Sangare L, Guindo H, Keita AS, Reimert CM, van Dam GJ, Deelder AM, Doumbo O, Dessein AJ: Urinary disease in 2 Dogon populations with different exposure to Schistosoma haematobium infection: progression of bladder and kidney diseases in children and adults. J Infect Dis 2005, 192(12):2152-2159.
• [66]Isnard A, Kouriba B, Doumbo O, Chevillard C: Association of rs7719175, located in the IL13 gene promoter, with Schistosoma haematobium infection levels and identification of a susceptibility haplotype. Genes Immun 2011, 12(1):31-39.
• [67]Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, Hurles ME, McVean GA, 1000 Genomes Project Consortium: A map of human genome variation from population-scale sequencing. Nature 2010, 467(7319):1061-1073.
• [68]Ghosh K: Evolution and selection of human leukocyte antigen alleles by Plasmodium falciparum infection. Hum Immunol 2008, 69(12):856-860.